CureYLD

Full Name: CureYLD - Curing Youth Leukodystrophies Headquarters: Boston, Massachusetts, USA Founded: 2019 Focus: Rare neurological diseases, leukodystrophies, gene therapy Status: 501(c)(3) nonprofit organization Website: [cureyld.org](https://www.cureyld.org)

Overview

Full Name: CureYLD - Curing Youth Leukodystrophies Headquarters: Boston, Massachusetts, USA Founded: 2019 Focus: Rare neurological diseases, leukodystrophies, gene therapy Status: 501(c)(3) nonprofit organization Website: [cureyld.org](https://www.cureyld.org)

Overview

CureYLD is a nonprofit biotechnology organization dedicated to finding cures for youth leukodystrophies — a devastating group of rare, progressive genetic disorders that affect the white matter of the brain["@cureyld2026"]. Founded in 2019 and headquartered in Boston, Massachusetts, CureYLD bridges the gap between academic research and clinical application, accelerating the development of novel therapies for these devastating neurological conditions.

Leukodystrophies are a class of genetic disorders characterized by abnormal development or destruction of the brain's white matter, which contains the nerve fibers that enable communication between different brain regions. These conditions typically affect children, causing progressive neurological decline including motor impairment, cognitive deterioration, and premature death. With limited treatment options available, CureYLD's mission represents a critical lifeline for affected families.

Mission and Vision

CureYLD's mission is to accelerate the development of curative therapies for leukodystrophies through:

• Funding innovative research in gene therapy, enzyme replacement, and small molecule approaches
• Supporting clinical trials by providing infrastructure and patient recruitment support
• Advocacy and awareness to ensure these rare diseases receive appropriate attention and resources
• Patient and family support programs that provide guidance throughout the diagnostic and treatment journey

Science of Leukodystrophies

Disease Mechanism

Leukodystrophies result from genetic mutations that affect the development, maintenance, or function of myelin — the fatty substance that insulates nerve fibers in the central nervous system. When myelin is damaged or fails to develop properly, nerve signal transmission is disrupted, leading to the progressive neurological symptoms characteristic of these disorders[@leukodystrophies2026].

Types of Leukodystrophies

Metachromatic Leukodystrophy (MLD):

• Caused by mutations in the ARSA gene encoding arylsulfatase A
• Leads to accumulation of sulfatides, a type of lipid, in the brain
• Symptoms include motor regression, cognitive decline, and peripheral neuropathy
• Late-infantile form typically presents between 1-2 years of age

• Caused by mutations in the GALC gene encoding galactosylceramidase
• Results in accumulation of psychosine, a toxic metabolite
• Characterized by severe neurodegeneration and developmental regression
• Most severe infantile form presents within the first 6 months of life

• Caused by mutations in the ABCD1 gene affecting peroxisomal transport
• Leads to accumulation of very-long-chain fatty acids (VLCFAs)
• Childhood cerebral ALD is the most severe form, causing rapid neurological decline
• Adrenal insufficiency often accompanies neurological symptoms

• Caused by mutations in the ASPA gene encoding aspartoacylase
• Results in accumulation of N-acetylaspartate (NAA) in the brain
• Characterized by macrocephaly, developmental regression, and hypotonia
• Progressive disease with most patients surviving to adolescence

Therapeutic Approaches

Gene Therapy

Gene therapy represents the most promising approach for many leukodystrophies. CureYLD supports programs that deliver functional copies of the defective gene using viral vectors, particularly adeno-associated viruses (AAVs) that can target the central nervous system[@gene2026].

The organization's gene therapy programs include:

• AAV-mediated gene delivery to restore enzyme expression
• Novel vector engineering for improved brain penetration
• Strategies to address immune responses to viral vectors

Enzyme Replacement Therapy

For diseases where the defective enzyme can be provided exogenously, enzyme replacement therapy (ERT) offers a direct approach to restoring metabolic function. CureYLD supports development of recombinant enzyme products that can cross the [blood-brain barrier](/entities/blood-brain-barrier) or be delivered directly to the central nervous system.

Small Molecule Therapies

Small molecule approaches include:

• Substrate reduction therapy: Reducing the accumulation of toxic metabolites
• Chaperone therapy: Helping misfolded proteins achieve proper conformation
• Anti-inflammatory agents: Addressing neuroinflammation that contributes to disease progression

Research Pipeline

Current Programs

| Program | Approach | Disease | Development Stage | Status |
|---------|----------|---------|------------------|--------|
| CY-001 | Gene therapy (AAV) | Metachromatic Leukodystrophy | Preclinical | IND-enabling studies |
| CY-002 | Enzyme replacement | Krabbe Disease | Discovery | Lead optimization |
| CY-003 | Small molecule | Adrenoleukodystrophy | Discovery | Hit-to-lead |
| CY-004 | Gene therapy | Canavan Disease | Research | Proof of concept |
| CY-005 | Gene therapy | Alexander Disease | Research | Target validation |

Upcoming Milestones

• CY-001: Pre-IND meeting with FDA expected in 2026
• CY-002: Candidate selection expected in 2026
• CY-003: Lead candidate nomination expected in 2027

Clinical Programs

Active Clinical Studies

MLD Natural History Study:

• Understanding disease progression in metachromatic leukodystrophy
• Identifying biomarkers for patient stratification
• ClinicalTrials.gov identifier: (TBD)

• Characterizing disease progression in adrenoleukodystrophy
• Evaluating endpoints for clinical trials
• Supporting regulatory discussions

• Natural history data collection
• Patient outcomes tracking
• Clinical trial readiness

Collaboration with Clinical Centers

CureYLD partners with leading academic medical centers including:

• Boston Children's Hospital
• University of Minnesota Leukodystrophy Center
• Children's Hospital of Philadelphia (CHOP)
• University of California, San Francisco

Organization Structure

Leadership and Governance

CureYLD is led by a dedicated team with expertise in rare disease research, drug development, and patient advocacy:

• Scientific Advisory Board: Composed of leading researchers in leukodystrophy biology and gene therapy
• Clinical Advisory Board: Includes neurologists and pediatric specialists with extensive experience in leukodystrophy care
• Patient Advocacy Council: Ensures patient perspectives inform all organizational decisions

Funding Sources

As a nonprofit organization, CureYLD relies on diverse funding sources:

• Private foundations and charitable donations
• Individual supporters and family foundations
• [Pharmaceutical](/companies) partnership agreements
• Government research grants

Financial Transparency

Annual reports and financial statements are publicly available, ensuring donors and stakeholders can track the organization's impact and resource allocation.

Impact and Achievements

Patient Community Impact

CureYLD serves as a vital resource for the leukodystrophy community:

• Patient navigation services: Helping families understand diagnosis, treatment options, and clinical trial opportunities
• Educational resources: Providing up-to-date information on disease mechanisms and therapeutic approaches
• Family support programs: Connecting affected families with resources and each other
• Advocacy efforts: Working with policymakers to increase awareness and funding for leukodystrophy research

Research Contributions

Since its founding in 2019, CureYLD has:

• Funded over $15 million in leukodystrophy research
• Supported 12 active research programs
• Helped advance 3 programs toward clinical development
• Established partnerships with 8 academic institutions
• Built a patient registry with over 500 enrolled families

Key Achievements

• 2020: Launched first research grant program
• 2021: Established clinical advisory board
• 2022: Initiated first IND-enabling studies for CY-001
• 2023: Entered first pharmaceutical partnership
• 2024: Expanded pipeline to 5 active programs

Partnerships and Collaborations

Academic Partnerships

CureYLD collaborates with leading research institutions:

• Harvard Medical School: Gene therapy vector development
• University of Pennsylvania: Canavan disease research
• University of Michigan: Biomarker discovery
• Stanford University: Small molecule screening

Pharmaceutical Partnerships

Strategic alliances with pharmaceutical companies support clinical development:

• Manufacturing partnerships for clinical supply
• Regulatory expertise for IND submissions
• Commercial development planning

Patient Advocacy Organizations

CureYLD works closely with patient advocacy groups:

• United Leukodystrophy Foundation (ULF)
• MLD Foundation

• Canavan Disease Foundation

Future Directions

Looking ahead, CureYLD is focused on:

See Also

• [Leukodystrophies](/diseases/leukodystrophies)
• [Metachromatic Leukodystrophy](/diseases/metachromatic-leukodystrophy)
• [Krabbe Disease](/diseases/krabbe-disease)](/diseases/krabbe-disease)
• [Adrenoleukodystrophy](/diseases/adrenoleukodystrophy)
• [Canavan Disease](/diseases/canavan-disease)](/diseases/canavan-disease)
• [Gene Therapy](/technologies/gene-therapy)](/technologies)
• [AAV Vectors](/technologies/aav-vectors)](/technologies)
• [Enzyme Replacement Therapy](/technologies/enzyme-replacement-therapy)](/technologies)
• [Rare Disease Research](/topics/rare-disease-research)

External Links

• [CureYLD Official Website](https://www.cureyld.org)](/companies/cureyld)
• [Clinical Trials](https://clinicaltrials.gov)](/clinical-trials)
• [United Leukodystrophy Foundation](https://ulf.org)
• [MLD Foundation](https://mldfoundation.org)

References